Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 265
- Locations
- 6
- Primary Endpoint
- adherence to drug treatment in secondary prevention after TIA
Study Overview
Brief Summary
Use of drugs is an important factor in secondary prophylaxis after transient ischemic attack (TIA), but studies show that adherence to the prescribed drugs is often poor. This randomised controlled trial aims to investigate whether a systematic follow up of drug treatment using medication reconciliation, medication reviews and patient counselling by clinical pharmacists, improves adherence and/or decreases cardiovascular events the first three months and the first year after TIA. Patient satisfaction will also be compared between the two groups.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Probable or possible transient ischemic attack
- •Residing in Central Norway
- •Examined within 2 weeks after the onset of symptoms
- •Modified Rankin Scale 3 or less and living at home
- •enrolled in the MIDNOR-TIA study NCT02038725
- •Informed consent
Exclusion Criteria
- Not provided
Arms & Interventions
drug use counselling
Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
Intervention: Drug use counselling (Behavioral)
Control group
The patients in the control group receive no intervention just treatment and follow up according to national standards
Outcomes
Primary Outcomes
adherence to drug treatment in secondary prevention after TIA
Time Frame: 3 months
self reporting of adherence
Secondary Outcomes
- adherence to drug treatment in secondary prevention after TIA(1 year)
- Incidence of stroke and cardiovascular events and deaths(1 year)
- patient satisfaction(1 year)
- Persistence(1 year)
- degree of disability or dependence in the daily activities(1 year)
- Persistence(3 months)
- Incidence of stroke and cardiovascular events and deaths(3 months)
- degree of disability or dependence in the daily activities(3 months)
- patient satisfaction(3 months)